Skip to content

aKLmRNA

aKLmRNA is an emerging therapeutic approach that involves the use of messenger RNA to modulate the expression of the Klotho protein, which is associated with aging and longevity. This approach aims to enhance the body's natural production of Klotho, potentially offering benefits in slowing down the aging process and improving healthspan.

Intelligence Profile

Research Papers

Currently, there is limited information available on the compound "aKLmRNA." No published research papers on PubMed have been retrieved concerning this therapy. However, there is a registered clinical trial (NCT07544420) titled "aKLmRNA-mediated Protein Replacement Therapy." This trial is in Phase 1 and is not yet recruiting participants. Phase 1 trials are primarily designed to assess the safety, tolerability, and optimal dosage of a new therapy. No additional details regarding sample size or specific study design have been provided at this time.

Further information will likely emerge as the trial progresses and results are published. For specific medical advice or insights beyond available evidence, consulting a healthcare professional is recommended.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.